|
1
|
Dolecek TA, Propp JM, Stroup NE and
Kruchko C: CBTRUS statistical report: Primary brain and central
nervous system tumors diagnosed in the United States in 2005–2009.
Neuro Oncol. 14(Suppl 5): v1–v49. 2012. View Article : Google Scholar :
|
|
2
|
Kanu OO, Mehta A, Di C, Lin N, Bortoff K,
Bigner DD, Yan H and Adamson DC: Glioblastoma multiforme: A review
of therapeutic targets. Expert Opin Ther Targets. 13:701–718. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Adamson C, Kanu OO, Mehta AI, Di C, Lin N,
Mattox AK and Bigner DD: Glioblastoma multiforme: A review of where
we have been and where we are going. Expert Opin Investig Drugs.
18:1061–1083. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al European Organisation for Research and Treatment of Cancer
Brain Tumor and Radiotherapy Groups; National Cancer Institute of
Canada Clinical Trials Group: Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kanu OO, Hughes B, Di C, Lin N, Fu J,
Bigner DD, Yan H and Adamson C: Glioblastoma multiforme
oncogenomics and signaling pathways. Clin Med Oncol. 3:39–52.
2009.PubMed/NCBI
|
|
6
|
Cancer Genome Atlas Research Network:
Comprehensive genomic characterization defines human glioblastoma
genes and core pathways. Nature. 455:1061–1068. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Matsukado Y, MacCarty CS and Kernohan JW:
The growth of glioblastoma multiforme (astrocytomas, grades 3 and
4) in neurosurgical practice. J Neurosurg. 18:636–644. 1961.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Di C, Mattox AK, Harward S and Adamson C:
Emerging therapeutic targets and agents for glioblastoma migrating
cells. Anticancer Agents Med Chem. 10:543–555. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mattox AK, Li J and Adamson DC: Stopping
cancer in its tracks: Using small molecular inhibitors to target
glioblastoma migrating cells. Curr Drug Discov Technol. 9:294–304.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lin N, Di C, Bortoff K, Fu J, Truszkowski
P, Killela P, Duncan C, McLendon R, Bigner D, Gregory S, et al:
Deletion or epigenetic silencing of AJAP1 on 1p36 in glioblastoma.
Mol Cancer Res. 10:208–217. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ernst A, Hofmann S, Ahmadi R, Becker N,
Korshunov A, Engel F, Hartmann C, Felsberg J, Sabel M, Peterziel H,
et al: Genomic and expression profiling of glioblastoma stem
cell-like spheroid cultures identifies novel tumor-relevant genes
associated with survival. Clin Cancer Res. 15:6541–6550. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bharti S, Handrow-Metzmacher H,
Zickenheiner S, Zeitvogel A, Baumann R and Starzinski-Powitz A:
Novel membrane protein shrew-1 targets to cadherin-mediated
junctions in polarized epithelial cells. Mol Biol Cell. 15:397–406.
2004. View Article : Google Scholar :
|
|
13
|
McDonald JM, Dunlap S, Cogdell D, Dunmire
V, Wei Q, Starzinski-Powitz A, Sawaya R, Bruner J, Fuller GN,
Aldape K, et al: The SHREW1 gene, frequently deleted in
oligodendrogliomas, functions to inhibit cell adhesion and
migration. Cancer Biol Ther. 5:300–304. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Okawa ER, Gotoh T, Manne J, Igarashi J,
Fujita T, Silverman KA, Xhao H, Mosse YP, White PS and Brodeur GM:
Expression and sequence analysis of candidates for the 1p36.31
tumor suppressor gene deleted in neuroblastomas. Oncogene.
27:803–810. 2008. View Article : Google Scholar
|
|
15
|
Benjelloun A, Delavelle J, Lazeyras F and
Dietrich PY: Possible efficacy of temozolomide in a patient with
gliomatosis cerebri. Neurology. 57:1932–1933. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schreiner A, Ruonala M, Jakob V, Suthaus
J, Boles E, Wouters F and Starzinski-Powitz A: Junction protein
shrew-1 influences cell invasion and interacts with
invasion-promoting protein CD147. Mol Biol Cell. 18:1272–1281.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gross JC, Schreiner A, Engels K and
Starzinski-Powitz A: E-cadherin surface levels in epithelial growth
factor-stimulated cells depend on adherens junction protein
shrew-1. Mol Biol Cell. 20:3598–3607. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jakob V, Schreiner A, Tikkanen R and
Starzinski-Powitz A: Targeting of transmembrane protein shrew-1 to
adherens junctions is controlled by cytoplasmic sorting motifs. Mol
Biol Cell. 17:3397–3408. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hiss JA, Resch E, Schreiner A, Meissner M,
Starzinski-Powitz A and Schneider G: Domain organization of long
signal peptides of single-pass integral membrane proteins reveals
multiple functional capacity. PLoS One. 3:e27672008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Resch E, Quaiser S, Quaiser T, Schneider
G, Starzinski-Powitz A and Schreiner A: Synergism of shrew-1's
signal peptide and transmembrane segment required for plasma
membrane localization. Traffic. 9:1344–1353. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Milde T, Pfister S, Korshunov A, Deubzer
HE, Oehme I, Ernst A, Starzinski-Powitz A, Seitz A, Lichter P, von
Deimling A and Witt O: Stepwise accumulation of distinct genomic
aberrations in a patient with progressively metastasizing
ependymoma. Genes Chromosomes Cancer. 48(3): 229–238. 2009.
View Article : Google Scholar
|
|
22
|
Cogdell D, Chung W, Liu Y, McDonald JM,
Aldape K, Issa JP, Fuller GN and Zhang W: Tumor-associated
methylation of the putative tumor suppressor AJAP1 gene and
association between decreased AJAP1 expression and shorter survival
in patients with glioma. Chin J Cancer. 30:247–253. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cozad SC, Townsend P, Morantz RA, Jenny
AB, Kepes JJ and Smalley SR: Gliomatosis cerebri. Results with
radiation therapy. Cancer. 78:1789–1793. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lefranc F, Brotchi J and Kiss R: Possible
future issues in the treatment of glioblastomas: Special emphasis
on cell migration and the resistance of migrating glioblastoma
cells to apoptosis. J Clin Oncol. 23:2411–2422. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dong Z, Pang JS, Ng MH, Poon WS, Zhou L
and Ng HK: Identification of two contiguous minimally deleted
regions on chromosome 1p36.31-36.32 in oligodendroglial tumours. Br
J Cancer. 91:1105–1111. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brat DJ, Seiferheld WF, Perry A, Hammond
EH, Murray KJ, Schulsinger AR, Mehta MP and Curran WJ; Radiation
Therapy Oncology Group: Analysis of 1p, 19q9p, and 10q as
prognostic markers for high-grade astrocytomas using fluorescence
in situ hybridization on tissue microarrays from Radiation Therapy
Oncology Group trials. Neuro Oncol. 6:96–103. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
White PS, Thompson PM, Gotoh T, Okawa ER,
Igarashi J, Kok M, Winter C, Gregory SG, Hogarty MD, Maris JM, et
al: Definition and characterization of a region of 1p36.3
consistently deleted in neuroblastoma. Oncogene. 24:2684–2694.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fujita T, Igarashi J, Okawa ER, Gotoh T,
Manne J, Kolla V, Kim J, Zhao H, Pawel BR, London WB, et al: CHD5,
a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J
Natl Cancer Inst. 100:940–949. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Giese A, Bjerkvig R, Berens ME and
Westphal M: Cost of migration: Invasion of malignant gliomas and
implications for treatment. J Clin Oncol. 21:1624–1636. 2003.
View Article : Google Scholar : PubMed/NCBI
|
